These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 29120264)

  • 41. Current treatment of tardive dyskinesia.
    Margolius A; Fernandez HH
    Parkinsonism Relat Disord; 2019 Feb; 59():155-160. PubMed ID: 30591350
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.
    Frank S; Stamler D; Kayson E; Claassen DO; Colcher A; Davis C; Duker A; Eberly S; Elmer L; Furr-Stimming E; Gudesblatt M; Hunter C; Jankovic J; Kostyk SK; Kumar R; Loy C; Mallonee W; Oakes D; Scott BL; Sung V; Goldstein J; Vaughan C; Testa CM;
    JAMA Neurol; 2017 Aug; 74(8):977-982. PubMed ID: 28692723
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.
    Grigoriadis DE; Smith E; Hoare SRJ; Madan A; Bozigian H
    J Pharmacol Exp Ther; 2017 Jun; 361(3):454-461. PubMed ID: 28404690
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia.
    Meyer JM
    CNS Spectr; 2016 Dec; 21(S1):13-24. PubMed ID: 28044943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-World Experience With VMAT2 Inhibitors.
    Niemann N; Jankovic J
    Clin Neuropharmacol; 2019; 42(2):37-41. PubMed ID: 30870235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment.
    Correll CU; Kane JM; Citrome LL
    J Clin Psychiatry; 2017; 78(8):1136-1147. PubMed ID: 29022654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Valbenazine and Deutetrabenazine as possible treatments for neuroleptic-induced supersensitivity psychosis and antipsychotic dependence.
    Skaff R
    CNS Spectr; 2019 Aug; 24(4):352-353. PubMed ID: 30458899
    [No Abstract]   [Full Text] [Related]  

  • 48. Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.
    Coppen EM; Roos RA
    Drugs; 2017 Jan; 77(1):29-46. PubMed ID: 27988871
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care.
    McEvoy JP
    J Clin Psychiatry; 2020 Nov; 81(6):. PubMed ID: 33147658
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.
    Claassen DO; Carroll B; De Boer LM; Wu E; Ayyagari R; Gandhi S; Stamler D
    J Clin Mov Disord; 2017; 4():3. PubMed ID: 28265459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.
    Jankovic J; Clarence-Smith K
    Expert Rev Neurother; 2011 Nov; 11(11):1509-23. PubMed ID: 22014129
    [TBL] [Abstract][Full Text] [Related]  

  • 52. deutetrabenazine for the treatment of chorea associated with Huntington's disease.
    Gupta H; Perkins W; Stark C; Kikkeri S; Kakazu J; Kaye A; Kaye AD
    Health Psychol Res; 2022; 10(5):36040. PubMed ID: 35774908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence.
    McEvoy JP
    J Clin Psychiatry; 2020 Sep; 81(6):. PubMed ID: 32991793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Valbenazine-induced parkinsonism.
    Akbar U; Kim DS; Friedman JH
    Parkinsonism Relat Disord; 2020 Jan; 70():13-14. PubMed ID: 31785443
    [No Abstract]   [Full Text] [Related]  

  • 55. Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors.
    Caroff SN
    Clin Psychopharmacol Neurosci; 2020 May; 18(2):322-326. PubMed ID: 32329312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 29024264
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect.
    Schneider F; Stamler D; Bradbury M; Loupe PS; Hellriegel E; Cox DS; Savola JM; Gordon MF; Rabinovich-Guilatt L
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):647-659. PubMed ID: 33038289
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deutetrabenazine in the treatment of Huntington's disease.
    Richard A; Frank S
    Neurodegener Dis Manag; 2019 Feb; 9(1):31-37. PubMed ID: 30624137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of Secondary Chorea: A Review of the Current Literature.
    Feinstein E; Walker R
    Tremor Other Hyperkinet Mov (N Y); 2020 Jul; 10():22. PubMed ID: 32775036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient's Perspective.
    Josiassen RC; Filmyer DM; Gillean J; Shah SS; Dietterich TE; Shaughnessy RA
    Am J Case Rep; 2017 Nov; 18():1185-1189. PubMed ID: 29114100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.